Large food and alcohol companies are undermining public health
Large food and alcohol companies are undermining public health
Using genetics to close the knowledge gap on cancer causation
The IMpower-132 trial for non small cell lung cancer
Current clinical landscape for ALK non-small cell lung cancer patients
Latest advances in treatment for ALK positive NSCLC
Highlights in early non-metastatic NSCLC and thoracic tumours
Anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with SCLC
Highlights in SCLC from ESMO 2018
ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel maintenance in NSCLC
ASCEND-8: safety data of ceritinib with or without food in NSCLC
Lung highlights from ESMO 2018
Erlotinib for neoadjuvant treatment of EGFR NSCLC